Daily Roundup

CU6.ASX ABB.ASX TLX.ASX CAT.ASX SMP.ASX

Clarity Pharmaceuticals Hits Key Milestone in Prostate Cancer Imaging

Clarity Pharmaceuticals is celebrating a major win for its prostate cancer imaging technology. The company's Co-PSMA trial has achieved its primary endpoint, demonstrating that its 64Cu-SAR-bisPSMA PET/CT scan detects significantly more lesions per patient compared to the standard-of-care 68Ga-PSMA-11 PET/CT.

These results support the hypothesis that 64Cu-SAR-bisPSMA can improve early detection of prostate cancer recurrence and more accurately stage the disease, especially in patients with low PSA levels. This is crucial, as existing PSMA PET agents are known to have low sensitivity in this patient population.

The Co-PSMA findings corroborate earlier results from Clarity's COBRA trial, which showed 64Cu-SAR-bisPSMA could identify lesions more than 6 months earlier than standard PSMA PET agents. Clarity believes these improvements in sensitivity can play a pivotal role in guiding treatment decisions and ultimately improving patient outcomes.

As Clarity continues to generate high-quality data, the company is focused on progressing the clinical development of 64Cu-SAR-bisPSMA, including its CLARIFY and AMPLIFY Phase III trials. With the potential to become the new standard-of-care in PSMA PET imaging, Clarity is optimistic about the future growth opportunities for this innovative diagnostic product.

Aussie Broadband Delivers Robust FY25 Results, Expands Wholesale Footprint

Aussie Broadband has reported a strong financial performance for the 2025 fiscal year, with revenue up 18.7% to $1.2 billion and underlying EBITDA reaching $138.2 million.

The company's Residential segment continued to see solid growth, while the Business, Enterprise and Government segment also won new customers. Aussie Broadband's Wholesale segment received a significant boost from a 6-year agreement with More Telecom, which will see around 290,000 More and Tangerine connections hosted on the Aussie network by the end of FY26.

To power this migration, Aussie Broadband has launched its new Nitrogen wholesale platform, which was first used to migrate Symbio's NBN services earlier this year. The More Telecom agreement is expected to contribute $12 million in annualised EBITDA from FY27, though there will be no material financial impact in FY26.

Aussie Broadband remains committed to its 'Look-to-28' strategy, with ambitions to grow revenue beyond $1.6 billion and achieve an 11%+ share of the NBN market by FY28. The company is also working to reduce the contribution of its Residential segment to no more than 60% of total revenue.

Telix Reports Strong Q3 Results, Upgrades FY 2025 Guidance

Telix Pharmaceuticals has delivered an impressive Q3 performance, reporting unaudited group revenue of approximately $206 million, up 53% year-over-year. The company has also increased its FY 2025 revenue guidance to $800 million to $820 million, up from the previous range of $770 million to $800 million.

Key highlights for Telix include:

• Gozellix® now fully reimbursed by the Centers for Medicare and Medicaid Services (CMS), with a Level II HCPCS code and Transitional Pass-Through (TPT) payment status
• Illuccix® approved in 19 European markets and the UK, with commercial launch underway
• First patients dosed in the BiPASS™ trial for prostate cancer diagnosis and detection
• Continued progress on the company's therapeutic pipeline and Precision Medicine business

Telix's strong performance and increased guidance reflect the growing commercial traction of its PSMA imaging products, Illuccix and Gozellix, as well as the anticipated contribution from its recent acquisition of RLS.

Catapult Raises $130M to Fund Strategic Acquisition and Strengthen Balance Sheet

Sports technology company Catapult Sports has successfully completed a A$130 million (US$84 million) institutional placement, raising funds to fuel its growth strategy.

The placement, which was well supported by both existing and new institutional investors, will be used to finance Catapult's strategic acquisition of IMPECT GmbH, a leading innovator in soccer analytics software. The remaining proceeds will be used to strengthen the company's balance sheet and provide capacity for future M&A opportunities.

In addition to the placement, Catapult is also undertaking a non-underwritten Share Purchase Plan of up to A$20 million, which will be offered to eligible Australian and New Zealand shareholders, as well as US-resident directors.

This capital raising positions Catapult well to continue executing on its growth plans, both through targeted acquisitions and by investing in its core business to maintain its position as a leading provider of sports performance and analytics solutions.

Smartpay Shareholders Approve $1.20 per Share Acquisition Scheme

Smartpay Holdings has received overwhelming shareholder approval for its proposed Scheme of Arrangement with Shift4 Holdings and Shift4 Payments. At a special meeting, 95.21% of votes cast were in favor of the $1.20 per share cash offer, exceeding the required 75% threshold.

The Smartpay Board had unanimously recommended the Scheme, which represents a significant premium to the company's pre-announcement share price and is near the mid-point of the independent valuation range. The Scheme provides Smartpay shareholders with the opportunity to realize certain value for their shares in cash, while removing their exposure to the company's future operating risks.

With shareholder approval secured, the next steps in the Scheme process will be to obtain final court approval. Assuming all conditions are met, the Scheme is expected to be implemented by early November 2025, marking the end of Smartpay's time as a listed company.